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IgG4 disease can have apparently “normal” levels of IgG4 due to antigen 
excess conditions. IgG4 measurement therefore appears falsely low. UK 
NEQAS data and other reports have suggested this problem occurred despite 
pre:existing antigen excess detection steps. 
	
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We examined the prevalence and characteristics of prozoning in our 
laboratory and patient cohorts, to determine the clinical relevance of the 
problem. 
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
We establish that the prevalence of raised IgG4 in routine IgG4 analysis is low 
(<1%) using one of the 2 routine methods in use in the UK.  We show that 
subsequent assay modification appears to have reduced the likelihood of 
misleading readings. However, the original version of the assay prozoned to 
low levels (below 0.64g/L) in 41% of high IgG4 samples in our patients. This 
may explain the previous reports of low sensitivity of raised IgG4 for IgG4RD, 
and predictive values should be re:evaluated in this disease using modified 
prozone:resistant protocols. 

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All laboratories providing IgG4 measurements should verify that their assays 
are fit for the clinical quality requirement of detection raised IgG4 levels and 
must verify the upper limit of their reference ranges and freedom from 
prozoning. 

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Measurement of the IgG4 Immunoglobulin subclass was thought to be of 
limited utility until the recent description of IgG4 related disease (IgG4:RD) (1:
15). A cardinal criterion of IgG4 disease, unsurprisingly, is a raised IgG4 level. 
However most clinicians do not understand that IgG4 measurement is more 
complex than other isotypes. IgG4 is an unusual form of immunoglobulin with 
unique properties. There are at least 2 different assays, producing different 
values, with different reference ranges. Furthermore, UK National External 
Quality Assessment Schemes (UK NEQAS), and other publications, have 
demonstrated the existence of antigen excess phenomena at moderate levels 
of IgG4, not much above the 95th centile of the reference range, sufficient to 
cause the raised IgG4 to be missed due to prozoning (4, 16, 17). 
 
Historically, IgG4 was measured alongside the other IgG subclasses (IgG1, 
IgG2 and IgG3) in the investigation of immune deficiency (18:20). Hence 
assays were optimised to detect low or normal levels of IgG4. The Binding 
Site IgG4 assay had a limited detection level above the normal range (upper 
detection limit 2.4g/L). However all IgG4 assays were also unable to measure 
the lower limit (21). Therefore quoted reference ranges have lower limits of 
“zero”. The use of IgG4 measurement to investigate IgG4:RD has now 
changed the measurement range of clinical relevance to include raised levels. 
 
Antigen excess, or prozoning, occurs in fluid phase immunoassays due to the 
Heidelberger:Kendall kinetics curve which shows the altered interaction 
between antigen and antibody at varying concentrations (22, 23).  In 
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nephelometric/turbidimetric systems, the same output signal, can be produced 
by two samples of differing antigen concentration, one in antibody excess the 
other in antigen excess. One measurement is correct the other is falsely low. 
 
In antigen excess conditions the antigen competes for binding sites on the 
antibody leading to resolubilisation of immune complexes and a reduction in 
signal detected (Figure 1). Many analysers have a mechanism to detect if the 
sample might be in antigen excess and a further dilution is performed to 
create antibody excess conditions for analysis.  If this check is absent, or fails, 
the result generated may be falsely low (Figure 1). 
 
In December 2012, UK NEQAS Immunology, Immunochemistry and Allergy 
(UK NEQAS IIA) suggested that some participants in the IgG subclasses 
scheme should investigate the possibility of antigen excess, because some 
laboratories submitted results in the normal range when the consensus for 
that method gave an elevated value for IgG4 (Sample 126:2, Method 
laboratory trimmed mean (MLTM) target 3.7g/L). This phenomenon was 
reproducible (samples 132:2 and 136:2) and affected laboratories randomly, 
with most laboratories detecting samples on one occasion and not others. 
 
In 2014, The Binding Site issued an article (21) detailing changes to their IgG4 
assay protocol to incorporate a two:step antigen excess check, which was 
aimed to resolve the problem. These changes are specific to The Binding Site 
IgG4 assay on the Siemens BNII analyser. The original antigen excess check 
protocol added the total volume of patient sample required to the reaction 
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mixture in one step. In the new protocol, a small amount of sample is added to 
the reaction mixture initially and then a second aliquot is added following a 
short interval. This allows any changes in reaction rates to be observed and 
determine if the sample might be in antigen excess and the result unreliable.  
 
This study had two main aims:  
1. To investigate antigen excess in the UK NEQAS IIA sample 126:2. 
2. To perform a series of studies to determine the prevalence of prozoning in 
routine use and to check that the new two:step antigen excess check resolved 
the issue. We tested samples from patients with a range of clinical indications 
including immune deficiency and IgG4:RD.  
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	
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Samples were analysed on the Siemens BNII nephelometer (Siemens, 
Camberley, Surrey, UK) using The Binding Site (Birmingham, UK) IgG4 
reagent according to the manufacturer’s instructions. All samples were initially 
tested at a starting dilution of 1/100 on the BNII unless otherwise stated. 
Samples were tested at further dilutions if automatically triggered when the 
sample appeared to exceed 0.64g/L. The laboratory performs three:level 
internal quality control prior to each run (low: 0.09g/L, CV= 8.05%; Medium: 
0.28g/L, CV= 4.53%; High: 0.49g/L, CV= 5.19%) and participates in the UK 
NEQAS IIA scheme for IgG subclasses with good performance.

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Aliquots of sample 126:2 were used for linearity experiments.  
 
Page 5 of 48 Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.


Linearity was also checked on two samples (S1 and S2), both apparently 
within the adult reference range of <1.3g/L (S1 at 0.71g/L, S2 at 1.19g/L) and 
one known to be in antigen excess (AgXS 1: initial result 0.27g/L but 4.6g/L 
with further dilution).  The samples were analysed neat and at serial dilutions 
in phosphate buffered saline. All samples were analysed using the original 
IgG4 protocol with a one:step antigen excess check at an on:board dilution of 
1/100. The results were plotted to determine linearity of the measurements for 
each sample. 
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We retrospectively re:tested 122 random samples at 1/400 dilution. All were 
originally reported with IgG4 in the range 0.05:0.64g/L (below the range which 
would trigger an antigen excess check by 1/400 auto:dilution). 
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199 unselected, consecutive samples requesting IgG subclasses (February 
2015 to March 2015) were tested using both the original one:step antigen 
excess protocol and the improved two:step antigen excess protocol.   
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2066 consecutive, unselected samples were measured with the new protocol 
(June 2014 – February 2015). Since the manufacturers had proposed that 
only samples with results >2.4g/L would have prozoned (21), we elected to 
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test all samples above 1.8g/L (i.e. 2.4g/L minus 2 standard deviation (SD) in 
our assay) to ensure that all samples around the 2.4g/L cut:off were included. 
41/2066 samples (2%) were >1.8g/L and were re:checked on the original 
protocol.  We defined a definitively prozoning sample as one which changed 
>2SD after antigen excess check, as this is the threshold at which we have a 
95% probability of a true difference in values. 

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Since a change in the method protocol had occurred in June 2014, we 
needed to verify that the reference range had not changed (June 2011:
February 2015). The results were compared using Analyse:it software version 
2.3 (Leeds, UK). 

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The original protocol appears linear up to 2.4g/L. 
Prozoning in UK NEQAS EQA distributions was a frequent occurrence (21 of 
63 measurements, 33%) in laboratories utilising affected method (Table 1). It 
occurred in different laboratories each time. One laboratory prozoned on all 3 
distributions and 1 prozoned on 2 distributions. The remaining 19 laboratories 
only prozoned on one occasion. 

In our laboratory antigen excess effects were again seen in 5 of 6 aliquots of 
the same UK NEQAS IIA sample that originally demonstrated the effect (126:
2) with the original antigen excess protocol. Confirming that earlier prozone 
Page 7 of 48 Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
	

detection was variable and not robust within a single laboratory. One of 6 
replicates obtained the correct value of 4.0g/L consistent with the assigned 
value. The remaining 5 aliquots gave severely suppressed results between 
0.58:0.64g/L. Samples >2.4g/L do not always trigger automatic dilution as the 
original protocol was not set up to detect raised levels (21). Subtle variability 
in the IgG4 levels measured in these aliquots may account for one sample 
being able to automatically trigger further dilutions by giving a value just above 
the dilution threshold, whereas the majority of the aliquots did not do this. 
  
AgXS 1 was linear up to 2.3g/L and then prozoned when analysed in the 
usual way, similar to the pattern seen in the UK NEQAS IIA sample 126:2 
(Figure 2). These results confirm the manufacturer’s data on the upper limit for 
the original antigen excess check (21). Samples known to have results below 
2.3g/L (S1 and S2) had linear recovery across all the dilutions tested (Figure 
2).  
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4 of 122 randomly selected “low IgG4” samples (3.3%) were in antigen excess 
and actually had raised IgG4 (Table 2). Samples 1 and 2 are so close to the 
0.64g/L threshold used to trigger automatic re:dilution that they may have 
been missed on some occasions due to normal assay variation (CV 5:10%). 
 
Like many laboratories, we do not routinely test total IgG on all requests for 
IgG subclasses, and they would mostly be done together when 
immunodeficiency was suspected. Therefore the difference between the sum 
of the individual IgG subclasses and total IgG was not available for 
Page 8 of 48Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.



comparison. It is doubtful that this is a reliable check unless the IgG4 is very 
high, since total IgG assays may have a CV of ≤10% and thus cannot reliably 
detect discrepancies of +/:2g/L at a 10g/L level. 
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We included samples with detectable and undetectable (<0.05g/L) IgG4. The 
samples with undetectable levels were included in case any prozoning sample 
resulted in an apparently unmeasurable signal. 
 
Only 1 of the 199 consecutive samples tested prozoned using the old protocol 
(from 6.8g/L to 0.2g/L). 7 samples were <0.05g/L, 143 samples 0.05:0.64g/L 
(1/100 measuring range), 47 samples 0.65 :2.4g/L (1/400 measuring range) 
and 2 gave results >2.4g/L (2.41g/L and 2.47g/L).  This suggests a 
prevalence of hidden antigen excess of only 0.5%. 
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The estimated prevalence of antigen excess was 0.8% (17/2066) when using 
the new protocol and re:running samples above 1.8g/L on the old protocol 
(Table 3). This confirms the estimated prevalence of 0.5% in 199 consecutive 
samples.  
 
14 of these samples would also have been identified by a ‘belt and braces’ 
check protocol of repeat testing of samples with an initial result below 0.64g/L 
on the original protocol (samples 1:14) (Table 3). 
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In total, 240 samples have been tested using both protocols to allow a direct 
comparison of results. A Passing:Bablock comparison plot (Figure 3) 
highlights that the majority of cases of antigen excess had a misleading result 
on the original protocol of <0.64g/L.  
 
Non:prozoning results up to an IgG4 of 2.5g/L are comparable using both 
protocols (but obviously does not exclude the possibility that true antigen 
excess could rarely produce a result in this range in some samples).  



+./8&2%%96&2%:
The normal range for adults (0 – 1.3g/L) was checked using data produced on 
the new protocol from June 2014 – February 2015 (Reference interval 
confirmation using Analyse:it v2.3, Anderson:Darling A2 non:parametric 
normality test). We confirmed that there was no significant change to the 
values obtained using both protocols in samples that did not prozone 
(Pearson correlation coefficient r = 0.98, Analyse it v2.3).  
Figure 4 indicates that although we can now detect IgG4 more reliably, there 
frequency of high IgG4 levels remains low in routine laboratory practice. The 
percentage of samples giving results >1.3g/L over the study duration has not 
changed significantly: June 11:Feb12 = 4.2%, June 12:Feb13 = 4.9%, June 
13:Feb14 = 4.7% and June 14:Feb15 = 4.2%. 


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The Binding Site IgG4 assay on the Siemens BNII analyser originally claimed 
an antigen excess check capability of 2.4g/L (21) It is now apparent that 
samples with IgG4 greater than 2.4g/L could potentially go undetected and 
result in the prozoning phenomenon as the assay was not configured to detect 
IgG4 disease with raised levels originally. New disorders are described 
frequently and may change the clinical use of established assays. Assay 
verification or validation needs to include assessment of performance against 
clinically derived acceptable performance characteristics (the clinical quality 
requirement).  The recent recognition of IgG4 disease and diagnostic use of 
with raised IgG4 levels is an exemplar of this phenomenon. Previous assay 
verification and development strategies may not have been targeted at this 
performance characteristic.  
 
Recently, The Binding Site have introduced an amended assay protocol with a 
two:step antigen excess check to increase the reliable measuring range of the 
assay to 49g/L (21) which appears to have successfully mitigated the 
problem. Users of other IgG4 assays should now also verify that prozoning is 
not an issue with their methods.  
 
It has been claimed that up to a quarter of raised IgG4 levels may exhibit 
significant prozoning in selected series (16). This could mean that cases of 
possible IgG4 disease are being missed, however it is important to note that 
IgG4:RD can present with normal or low IgG4 levels and current diagnostic 
guidelines include other criteria such as biopsy for this reason (6, 9:11). The 
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prevalence of prozoning described here is much lower than that stated by 
Khosroshahi et al, because we are establishing the prevalence in a random 
cohort of patients, most of whom are not suspected of having IgG4 related 
disease. However our evaluation of our selected raised IgG4 samples 
suggests that the prevalence of prozoning in this cohort may be even higher 
at >40%.  This would be a serious problem with detecting a rare disease and 
could explain the apparent lack of raised IgG4 in some “IgG4 Disease” cases 
(14:17).  In our cohort the prevalence of significantly prozoning samples was 
<1% of routine sampling, but 4 in 10 of those might have been previously 
missed.  
 
The positive predictive value of the test is reportedly <40% for IgG4:RD prior 
to effective antigen excess detection, but this may be an artefact of both test 
and cohort biases and is not generalizable. It was established using a cut:off 
of 1.35 and both Siemens and This Binding Site IgG4 reagent. (17). 

Diagnostic guidelines for autoimmune pancreatitis (9) and IgG4 related 
disease IgG4:RD (6) both utilise IgG4 measurement when investigating these 
conditions. Elevated IgG4 (> upper limit of the reference range or 1.35g/L) is 
suggestive of these diagnoses in the correct clinical context, but that raised 
results can be observed in other conditions and that IgG4 disease may still be 
present if the IgG4 is normal (24). Caution is required when clinicians interpret 
these results as it is clear that the upper limit of the reference range is 
different for the 2 main assays used (Binding site 0.039 – 0.864g/L and 
Siemens 0.03 – 2.01g/L) due to the lack of standardisation of calibration (25). 
If 1.35g/L is arbitrarily used, it falls within the “normal range” for the Siemens 
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assay. Laboratories should highlight their locally verified upper limits of 
normality on their reports. 

The Binding Site has now modified its assay successfully to ameliorate the 
problem (21). A new protocol employing a two:step check has been created 
and details are now supplied with the reagents, but users must choose to 
implement this change and it is not currently mandatory. It should be 
implemented in all laboratories measuring IgG4. 
 
We recommend that all users of this assay check their protocols, implement 
the use of effective antigen excess checks if they have not already done so, 
and verify both the upper limit of normal and the linear working range of their 
assay to ensure they are fit for purpose, in line with laboratory ISO 
accreditation requirements. Adjustment of the reference range was not 
required in our system. 

Any immunoassay that uses antibody:antigen interactions are at risk of similar 
phenomena if high levels of analytes are of clinical importance. Review of the 
clinical use of the assay in formulating a clinical quality requirement should 
highlight those assays where extra verification of prozoning or interferences is 
required. It is also important to consider antigen excess in other assay formats 
[22].  

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6% Heidelberger Kendall curve. There are 3 zones: antibody excess, 
equivalence and antigen excess. A sample in antigen excess can give the 
same result as one in antibody excess – as indicated by the grey arrow. 
Assays are designed to produce most results in antibody excess conditions to 
prevent falsely low results being reported.
 
6& Linearity experiment results. Shows that all samples are linear 
below 2.3g/L. 126:2 and AgXS1 were non:linear above this level and both 
dropped close to the 0.64g/L threshold that would trigger an antigen excess 
check. This may explain why some laboratories detected it on one occasion 
but not another. 
 
6= Scatter plot with Passing and Bablock fit in 240 samples tested on 
both protocols. All those which show inconsistent results were below 0.64g/L 
on the original protocol and greater than 2.4g/L on the new protocol. 


6/ High IgG4 results are detected more reliably since the change in 
protocol (Feb 2014). Upper linear limit of measurement in the original protocol 
(2.4g/L) indicated by the dashed line. Results indicate a large increase in 
values and detection of raised IgG4, without any known change of testing 
patterns or increase of requesting.  
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%UK NEQAS IIA Distributions with High IgG4 levels3Results form 
users of The Binding Site assay showed thatprozoning frequency varied 
between distributions from 21 – 46%. This also led to large assay %CV for 
these samples. *MLTM = Method Laboratory Trimmed Mean.
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$ ./%4%22
04*5 ./%4/22
04*5
% 0.63 4.62 
& 0.57 5.13 
= 0.27 6.05 
/ 0.15 12.5 
& Four prozoning samples which originally did not trigger auto dilution 
because they appeared to be <0.64g/L – the threshold which triggered an 
antigen excess check on the original protocol.  
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4 0.24 9.51 Yes 
5 0.28 5.69 Yes 
6 0.28 11.4 Yes 
7 0.31 2.57 Yes 
8 0.31 6.09 Yes 
9 0.36 3.79 Yes 
10 0.38 3.89 Yes 
11 0.41 4.62 Yes 
12 0.42 3.41 Yes 
13 0.46 3.53 Yes 
14 0.55 4.47 Yes 
15 1.39 2.08 Yes 
16 1.57 2.07 Yes 
17 1.72 1.85 No 
18 1.8 2.03 No 
19 1.8 1.9 No 
20 1.85 1.86 No 
21 1.87 2.06 No 
22 1.9 2 No 
23 1.92 1.93 No 
24 1.92 2.06 No 
25 2.01 2.21 No 
26 2.09 1.87 No 
27 2.1 2.07 No 
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= Assay modification detects samples >1.8g/L better than the original 
assay. 41% of samples>1.8g/L on the new protocol showed prozoning. 100% 
of samples prozoning were over 2.57g/L.  
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